García-Chávez J, Vela-Ojeda J, García-Manzano A, Majluf-Cruz A

Language: Spanish
References: 5
Page: 210-212
PDF size: 32.50 Kb.

ABSTRACT

A 28 year-old female without history of previous disease. In the seventh month of her first pregnancy she developed hemorrhagic tendency that worsened in the early postpartum period. Activated partial thromboplastin time was 110 sec (control = 35.8 sec) with negative tests for lupus anticoagulant. Factor VIII was ‹1 % and a factor VIII inhibitor titer was 84 Bethesda Units/mL (BU). Initial therapy included methylprednisolone, prednisone, and cyclophosphamide. After two weeks of treatment, clinical conditions of the patient improved slightly and she was discharged. Outpatient therapy included azathioprine, and prednisone for a period of 22 months but in-hospital management was several times required. We initiated rituximab 375 mg/m²/week/4 weeks. A clinical improvement and increased levels of factors VIII and XI were observed 10 weeks later and factor VIII inhibitor decreased to undetectable levels. After a 82-month follow-up period (since the first rituximab infusion), she is asymptomatic and factor VIII and factor XI plasma levels are 70% and 94%, respectively. FVIII inhibitor level is still undetectable. Rituximab seems an alternative for the treatment of acquired hemophilia refractory to standard treatment

REFERENCES

1. Cohen YC, Polliack A. Sustained complete remission of chronic refractory immune thrombocytopenic purpura (ITP) of 10 years duration after only two infusions of rituximab. Hematol J 2002; 3: 61-2.

2. Sperr RW, Lechner K, Pablinger I. Rituximab for the treatment of acquired antibodies to factor VIII. Haematolog 2007; 92: 66-71.

3. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EIB, et. al. Rituximab in the treatment of acquired factor VIII inhibitor. Blood 2002; 100: 3426-8.

4. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 15: 4424-8.

5. García-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, García- Ruiz Esparza M, Vela-Ojeda J. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a longterm follow-up analysis. Ann Hematol 2007; 86: 871-7.